Deutsche Bank AG lowered its holdings in shares of Tricida, Inc. (NASDAQ:TCDA) by 1.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 491,044 shares of the company’s stock after selling 8,493 shares during the quarter. Deutsche Bank AG owned about 0.98% of Tricida worth $2,121,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in TCDA. FMR LLC boosted its position in shares of Tricida by 9.7% during the 1st quarter. FMR LLC now owns 1,213,065 shares of the company’s stock valued at $46,849,000 after acquiring an additional 107,500 shares in the last quarter. BlackRock Inc. raised its stake in shares of Tricida by 8.3% in the first quarter. BlackRock Inc. now owns 2,714,638 shares of the company’s stock worth $14,360,000 after acquiring an additional 208,872 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Tricida by 44.1% in the first quarter. JPMorgan Chase & Co. now owns 18,135 shares of the company’s stock worth $95,000 after acquiring an additional 5,554 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Tricida by 11.7% during the 1st quarter. Geode Capital Management LLC now owns 491,612 shares of the company’s stock worth $2,600,000 after buying an additional 51,323 shares during the period. Finally, Ergoteles LLC grew its position in shares of Tricida by 189.1% during the 1st quarter. Ergoteles LLC now owns 31,600 shares of the company’s stock worth $167,000 after buying an additional 20,668 shares during the period. Institutional investors and hedge funds own 65.20% of the company’s stock.
Separately, Needham & Company LLC began coverage on shares of Tricida in a report on Tuesday, August 10th. They set a “buy” rating and a $20.00 price objective for the company.
Tricida (NASDAQ:TCDA) last announced its quarterly earnings data on Monday, August 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.17. Analysts predict that Tricida, Inc. will post -3.1 earnings per share for the current fiscal year.
Tricida Company Profile
Tricida, Inc is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.
Featured Article: What can cause a stock to outperform?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.